title: Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications.
authors.forename: M
authors.initials: M
authors.lastname: Pisano
authors.forename: P
authors.initials: P
authors.lastname: Baldinu
authors.forename: M C
authors.initials: MC
authors.lastname: Sini
authors.forename: P A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: F
authors.initials: F
authors.lastname: Tanda
authors.forename: G
authors.initials: G
authors.lastname: Palmieri
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D013873:Thionucleotides / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D013873:Thionucleotides; C408162:oblimersen